Pharmacists: The Most Accessible Healthcare Provider, Unless You Have a Substance Use Disorder

White pill bottle with white pills on a black background.
August 23, 2022
P4 students, Megan Yeung, Kami Johnston and Morgan Murchison co-author a peer-reviewed blog in Pulses encouraging educators to adapt to reflect the specific needs of people who use drugs and patients with substance use disorders. This blog also highlights UT Pharmacy as a U.S. leader in substance use disorder and harm reduction education for Pharm.D. students.

Fewer Than Half of U.S. Pharmacies Carry One of the Most Effective Drugs for Opioid Abuse

A pharmacist holding a box of medication.
June 13, 2022
Tara Law from Time writes about how few pharmacies carry buprenorphine, a life-saving drug to help treat opioid use disorder (OUD). Lucas Hill, Pharm.D., BCACP, director of the college's Pharmacy Addictions Research & Medicine (PhARM) program, offers his insight on the issue, and how the DEA's crackdown of the drug puts OUD patients at risk.

UT Pharmacy Scholars Celebrated at Honors Day

Aisha and Dean Poloyac with award certificate.
May 4, 2022
UT Pharmacy scholars received a set of white and green honor cords at the 74th Annual Honors Day celebrations to mark the very highest level of academic accomplishment.

Opioid Use Disorder Paper Earns ACCP Award

A box of naloxone vials.
October 8, 2021
A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.

Immunologic Resilience: A New Metric to Accurately Gauge COVID-19’s Path

The COVID-19 virus.
September 8, 2021
UT Pharmacy and UT Health Science Center San Antonio Assistant Professor Grace C. Lee, Pharm.D., Ph.D. is the first author of a recently published study that unveiled a novel concept, “immunologic resilience,” to accurately predict which COVID-19 patients will advance to severe disease and which will not.